The immune microenvironment has a pivotal role in hepatocellular carcinoma (HCC) progression and immune therapy resistance, and targeting this complex milieu holds great promise for improving therapeutic outcomes and patient prognoses in HCC management.

Theoretical modeling reveals how stochastic optimal cancer immune evasion via antigen downregulation gives rise to diverse post-escape cancer antigenic profiles in a manner dependent on the immune microenvironment.

A single-cell landscape of acral melanoma and the intermolecular regulatory relationships between microenvironments.

The heterogeneity of immune cell types in glioblastoma tumors depends on the tumor's genetic make-up and treatment status and is an incompletely mined source of novel therapeutic targets.

A biomimetic and patient-specific Glioblastoma-on-a-Chip microphysiological system provides an avenue for personalized screening of PD-1 immunotherapy and novel combinational therapies that maximize therapeutic outcomes in Glioblastoma patients.

Telomere-sensitive regulation of IL1R1 by the shelterin protein TERF2 modulates tumour macrophage inflitration in triple-negative breast cancer.

Chemotherapy remodels lung adenocarcinoma’s tumor microenvironment by driving metabolic reprogramming and shifting immune cell functions to modulate tumor progression and immune responses.

Tissue-resident natural killer cells are important mediators of CD8 T responses in human cancers and these cells can be harnessed to increase immunity against pancreatic ductal adenocarcinoma.

CD8+ Trm cells' erosion role in oral lichen planus via IFN-γ, TNF-α, and IL17 cytokines has been revealed, addressing a gap in recurrent erosion studies.

A novel multi-hormones secreting chromaffin-like cell type was identified using single-cell RNA sequencing, suggesting the molecular mechanism of ectopic ACTH and CRH pheochromocytoma associated with Cushing’s syndrome.